JP7611171B2 - 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子 - Google Patents

抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子 Download PDF

Info

Publication number
JP7611171B2
JP7611171B2 JP2021569109A JP2021569109A JP7611171B2 JP 7611171 B2 JP7611171 B2 JP 7611171B2 JP 2021569109 A JP2021569109 A JP 2021569109A JP 2021569109 A JP2021569109 A JP 2021569109A JP 7611171 B2 JP7611171 B2 JP 7611171B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
antigen
nos
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533418A5 (enExample
JP2022533418A (ja
Inventor
ワトキンス，ジェフリー・ディー
イェッセン，カティ
コ，ミラ
ランヌッティ，ブライアン
ヴォー，タン－トラン
ワトキンス，ジェー・モンティ
Original Assignee
ベロスビオ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベロスビオ・インコーポレイテッド filed Critical ベロスビオ・インコーポレイテッド
Publication of JP2022533418A publication Critical patent/JP2022533418A/ja
Publication of JP2022533418A5 publication Critical patent/JP2022533418A5/ja
Application granted granted Critical
Publication of JP7611171B2 publication Critical patent/JP7611171B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021569109A 2019-05-23 2020-05-22 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子 Active JP7611171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852039P 2019-05-23 2019-05-23
US62/852,039 2019-05-23
PCT/US2020/034281 WO2020237173A1 (en) 2019-05-23 2020-05-22 Anti-ror1/anti-cd3 bispecific binding molecules

Publications (3)

Publication Number Publication Date
JP2022533418A JP2022533418A (ja) 2022-07-22
JP2022533418A5 JP2022533418A5 (enExample) 2023-05-24
JP7611171B2 true JP7611171B2 (ja) 2025-01-09

Family

ID=71078637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569109A Active JP7611171B2 (ja) 2019-05-23 2020-05-22 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子

Country Status (11)

Country Link
US (1) US12655217B2 (enExample)
EP (1) EP3972999A1 (enExample)
JP (1) JP7611171B2 (enExample)
KR (1) KR20220012313A (enExample)
CN (1) CN113874399B (enExample)
AU (1) AU2020277489A1 (enExample)
BR (1) BR112021023026A2 (enExample)
CA (1) CA3139111A1 (enExample)
MX (1) MX2021014193A (enExample)
TW (1) TWI899079B (enExample)
WO (1) WO2020237173A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4069735A1 (en) * 2019-12-06 2022-10-12 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 bispecific antibody constructs
BR112022015416A2 (pt) * 2020-02-07 2022-10-11 Velosbio Inc Anticorpos anti-ror1 e composições
JP7858665B2 (ja) * 2021-02-02 2026-05-14 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
WO2023000791A1 (en) * 2021-07-23 2023-01-26 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
US20250051443A1 (en) * 2021-10-07 2025-02-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532644A (ja) 2012-08-24 2015-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2016520548A (ja) 2013-04-03 2016-07-14 アイビーシー ファーマスーティカルズ，インコーポレイテッド 疾患に対する免疫反応を誘導するための併用療法
US20160297881A1 (en) 2013-04-09 2016-10-13 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
JP2018502050A (ja) 2014-10-09 2018-01-25 エンクマフ アーゲー ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
JP2018516554A (ja) 2015-05-08 2018-06-28 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３に特異的なヒト化抗体またはその断片
JP2019506158A (ja) 2016-01-22 2019-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｒｏｒ１抗体、ｒｏｒ１×ｃｄ３二重特異性抗体、及びそれらの使用法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
MX386342B (es) * 2014-07-25 2025-03-18 Memorial Sloan Kettering Cancer Center Móleculas de unión a her2 y cd3 biespecíficas.
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3851457A1 (en) * 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
TWI804499B (zh) * 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
BR112022015416A2 (pt) * 2020-02-07 2022-10-11 Velosbio Inc Anticorpos anti-ror1 e composições

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532644A (ja) 2012-08-24 2015-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2016520548A (ja) 2013-04-03 2016-07-14 アイビーシー ファーマスーティカルズ，インコーポレイテッド 疾患に対する免疫反応を誘導するための併用療法
US20160297881A1 (en) 2013-04-09 2016-10-13 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
JP2018502050A (ja) 2014-10-09 2018-01-25 エンクマフ アーゲー ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
JP2018516554A (ja) 2015-05-08 2018-06-28 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３に特異的なヒト化抗体またはその断片
JP2019506158A (ja) 2016-01-22 2019-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｒｏｒ１抗体、ｒｏｒ１×ｃｄ３二重特異性抗体、及びそれらの使用法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The making of bispecific antibodies，mAbs，VOL. 9, NO. 2，2017年，pp. 182-212

Also Published As

Publication number Publication date
US12655217B2 (en) 2026-06-16
CN113874399A (zh) 2021-12-31
MX2021014193A (es) 2022-01-06
CA3139111A1 (en) 2020-11-26
TWI899079B (zh) 2025-10-01
KR20220012313A (ko) 2022-02-03
TW202110887A (zh) 2021-03-16
WO2020237173A1 (en) 2020-11-26
BR112021023026A2 (pt) 2022-01-04
AU2020277489A1 (en) 2021-11-25
US20220227866A1 (en) 2022-07-21
EP3972999A1 (en) 2022-03-30
CN113874399B (zh) 2025-07-11
JP2022533418A (ja) 2022-07-22

Similar Documents

Publication Publication Date Title
TWI899079B (zh) 抗ror1/抗cd3雙特異性結合分子
JP7551693B2 (ja) ＮＫｐ４６結合タンパク質の可変領域
JP7844558B2 (ja) リンパ球における阻害経路の中和
US12497454B2 (en) Anti-ROR1 antibodies and compositions
JP7701911B2 (ja) Ｃｅａｃａｍ５およびｃｄ３に対する二特異性抗体
JP7442443B2 (ja) 多重特異性抗体
AU2022285741A1 (en) Anti-ccr8 antibodies and uses thereof
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
JP2022542431A (ja) 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体
JP2018524326A (ja) 多重特異的ｎｋエンゲイジャータンパク質
CA3156983A1 (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
JP2024515396A (ja) 抗ｃｄ４７モノクローナル抗体及びその使用
JP2025508066A (ja) 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体
AU2021214622B2 (en) Means and method for modulating immune cell engaging effects.
JP2024503297A (ja) 多重特異性抗原結合タンパク質
CN117355540A (zh) 抗cd137抗体和使用方法
CA3256036A1 (en) Anti-PVRIG antibodies, pharmaceutical composition and associated uses
US20260028402A1 (en) Anti-cd100 antibody and use thereof
RU2831608C2 (ru) Анти-ror1/анти-cd3 биспецифические связывающие молекулы
CN119331101A (zh) 一种抗fgfr2/pd-1双特异性抗体
JP2024522172A (ja) ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック
TW202448504A (zh) Btn3a活化抗體及免疫檢查點抑制劑之組合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241223

R150 Certificate of patent or registration of utility model

Ref document number: 7611171

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150